NASDAQ: HOWL
Werewolf Therapeutics Inc Stock

$1.20-0.05 (-4%)
Updated Jun 25, 2025
HOWL Price
$1.20
Fair Value Price
$1.61
Market Cap
$53.62M
52 Week Low
$0.60
52 Week High
$4.18
P/E
-0.73x
P/B
0.94x
P/S
38.13x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.14M
Earnings
-$72.41M
Gross Margin
100%
Operating Margin
-5,905.07%
Profit Margin
-6,335.2%
Debt to Equity
0.87
Operating Cash Flow
-$60M
Beta
1.41
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

HOWL Overview

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics that stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Werewolf Therapeutics was incorporated in 2017 and is headquartered in Cambridge, MA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine HOWL's potential to beat the market

FStrong Sell
  • Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
HOWL
Ranked
#400 of 470

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important HOWL news, forecast changes, insider trades & much more!

HOWL News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HOWL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HOWL ($1.20) is undervalued by 26% relative to our estimate of its Fair Value price of $1.61 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
HOWL ($1.20) is significantly undervalued by 26% relative to our estimate of its Fair Value price of $1.61 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
HOWL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HOWL due diligence checks available for Premium users.

Valuation

HOWL fair value

Fair Value of HOWL stock based on Discounted Cash Flow (DCF)

Price
$1.20
Fair Value
$1.61
Undervalued by
25.69%
HOWL ($1.20) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HOWL ($1.20) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HOWL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

HOWL price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.73x
Industry
-127.98x
Market
31.79x

HOWL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.94x
Industry
4.44x
HOWL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

HOWL's financial health

Profit margin

Revenue
$0.0
Net Income
-$18.1M
Profit Margin
0%
HOWL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HOWL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$107.2M
Liabilities
$49.9M
Debt to equity
0.87
HOWL's short-term assets ($94.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HOWL's short-term assets ($94.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HOWL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$18.9M
Investing
$0.0
Financing
$0.0
HOWL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

HOWL vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
HOWLF$53.62M-4.40%-0.73x0.94x
SNTI$53.47M+2.50%-0.19x1.41x
ADVMF$53.90M+1.57%-0.35x2.04x
FBIOC$53.23M+0.56%-0.81x2.39x
TELOF$52.98M+1.14%-4.24x-328.84x

Werewolf Therapeutics Stock FAQ

What is Werewolf Therapeutics's quote symbol?

(NASDAQ: HOWL) Werewolf Therapeutics trades on the NASDAQ under the ticker symbol HOWL. Werewolf Therapeutics stock quotes can also be displayed as NASDAQ: HOWL.

If you're new to stock investing, here's how to buy Werewolf Therapeutics stock.

What is the 52 week high and low for Werewolf Therapeutics (NASDAQ: HOWL)?

(NASDAQ: HOWL) Werewolf Therapeutics's 52-week high was $4.18, and its 52-week low was $0.60. It is currently -71.41% from its 52-week high and 100.84% from its 52-week low.

How much is Werewolf Therapeutics stock worth today?

(NASDAQ: HOWL) Werewolf Therapeutics currently has 44,873,646 outstanding shares. With Werewolf Therapeutics stock trading at $1.20 per share, the total value of Werewolf Therapeutics stock (market capitalization) is $53.62M.

Werewolf Therapeutics stock was originally listed at a price of $16.10 in Apr 30, 2021. If you had invested in Werewolf Therapeutics stock at $16.10, your return over the last 4 years would have been -92.58%, for an annualized return of -47.8% (not including any dividends or dividend reinvestments).

How much is Werewolf Therapeutics's stock price per share?

(NASDAQ: HOWL) Werewolf Therapeutics stock price per share is $1.20 today (as of Jun 25, 2025).

What is Werewolf Therapeutics's Market Cap?

(NASDAQ: HOWL) Werewolf Therapeutics's market cap is $53.62M, as of Jun 26, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Werewolf Therapeutics's market cap is calculated by multiplying HOWL's current stock price of $1.20 by HOWL's total outstanding shares of 44,873,646.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.